Seagen Inc
NASDAQ:SGEN
Seagen Inc
Revenue
Seagen Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Seagen Inc
NASDAQ:SGEN
|
Revenue
$2.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
30%
|
CAGR 10-Years
24%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Seagen Inc
Revenue Breakdown
Breakdown by Geography
Seagen Inc
Breakdown by Segments
Seagen Inc
Total Revenue:
2B
USD
|
Net Product Sales:
1.7B
USD
|
Royalty Revenues:
164.6m
USD
|
Collaboration And License Agreement Revenues:
91.3m
USD
|
See Also
What is Seagen Inc's Revenue?
Revenue
2.3B
USD
Based on the financial report for Sep 30, 2023, Seagen Inc's Revenue amounts to 2.3B USD.
What is Seagen Inc's Revenue growth rate?
Revenue CAGR 10Y
24%
Over the last year, the Revenue growth was 23%. The average annual Revenue growth rates for Seagen Inc have been 7% over the past three years , 30% over the past five years , and 24% over the past ten years .